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Animal models of familial ADDevelopment of therapeutic strategies to prevent Alzheimer's disease (AD) is of great importance. We show that
mild inhibition ofmitochondrial complex I with smallmolecule CP2 reduces levels of amyloid beta and phospho-
Tau and averts cognitive decline in three animal models of familial AD. Low-mass molecular dynamics simula-
tions and biochemical studies conﬁrmed that CP2 competes with ﬂavin mononucleotide for binding to the
redox center of complex I leading to elevated AMP/ATP ratio and activation of AMP-activated protein kinase in
neurons and mouse brain without inducing oxidative damage or inﬂammation. Furthermore, modulation of
complex I activity augmented mitochondrial bioenergetics increasing coupling efﬁciency of respiratory chain
and neuronal resistance to stress. Concomitant reduction of glycogen synthase kinase 3β activity and restoration
of axonal trafﬁcking resulted in elevated levels of neurotrophic factors and synaptic proteins in adult AD mice.
Our results suggest that metabolic reprogramming induced by modulation of mitochondrial complex I activity
represents promising therapeutic strategy for AD.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disor-
der without cure. It is associated with progressive cognitive decline
that affects aging population. Without effective and immediate ap-
proaches aimed to prevent or modify the disease, by 2050 the number
of affected individuals can reach 100 million (Thies et al., 2013). Extra-
cellular amyloid beta (Aβ) plaques and intracellular neuroﬁbrillary tan-
gles comprised of hyperphosphorylated Tau protein (pTau) represent
themajor hallmarks of AD (Braak and Braak, 1991). The etiology of spo-
radic AD, which represents over 95% of all cases, is unknown with age, Mayo Clinic, 200 First St. SW,
ina).
. This is an open access article underbeing the single risk factor. Familial AD (FAD) is caused by mutations
in presenilin 1 and presenilin 2 (PS1 and PS2), and amyloid precursor
protein (APP), all of which are involved in the abnormal processing of
APP leading to increased levels of Aβ (Holtzman et al., 2011). The specif-
ic molecular mechanisms of sporadic and familial AD are still under in-
vestigation hindering the development of effective therapeutic
approaches. There is compelling data to demonstrate that increased
levels of Aβ compromise multiple cellular pathways. Thus, the down-
stream cognitive symptoms can be caused by non-Aβ factors including
oxidative stress, inﬂammation, mitochondrial dysfunction, and lipid
perturbations (Pimplikar et al., 2010). At the same time, emerging
data from multiple animal studies and clinical investigations suggest a
tight interconnection between Aβ and pTau, and therefore, develop-
ment of strategies to reduce levels of both could be beneﬁcial (Jack
and Holtzman, 2013; Mondragon-Rodriguez et al., 2012).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ther blocking activity ofβ or γ secretases, preventing Aβ aggregation, or
promoting Aβ clearance by immunotherapy have failed (Cummings
et al., 2014) emphasizing an urgent need to ﬁnd new therapies for AD.
One of the emerging therapeutic approaches involves modulation of
cellular energetics that includes activation of AMP-activated protein ki-
nase (AMPK), a master regulator of intracellular energy metabolism
(Shirwany and Zou, 2014). AMPK activation was shown to promote
neuronal survival after the exposure to Aβ peptides, induce
autophagy-dependent degradation of Aβ, and reduce tau phosphoryla-
tion (Park et al., 2012; Salminen et al., 2011; Vingtdeux et al., 2010,
2011). Resveratrol-induced activation of AMPK reduced cognitive im-
pairment in SAMP8mousemodel of AD (Porquet et al., 2013). AMPK ac-
tivation is also linked to an increase in life span in model organisms
(Kenyon, 2010; Mair et al., 2011; Salminen and Kaarniranta, 2012),
and to prevention of obesity and insulin resistance, conditions that sig-
niﬁcantly and independently increase risk of AD (Hardie, 2007;
Profenno et al., 2010). Metformin, an FDA approved drug to treat type
2 diabetes and potent activator of AMPK (Pernicova and Korbonits,
2014), reduces tau phosphorylation and improves neuronal insulin sig-
naling and AD-related neuropathological changes in vitro (Gupta et al.,
2011; Kickstein et al., 2010). However, activation of AMPK has been
shown to contribute to AD pathology and cause brain damage in AD
mice (Cai et al., 2012; Mairet-Coello et al., 2013). Similar, metformin
was also shown to increase Aβ levels by up-regulating the activity of
beta-site APP-cleaving enzyme 1 (BACE1), which could account for in-
creased risk of AD development in diabetic patients treated with met-
formin (Imfeld et al., 2012; Moore et al., 2013). Thus, the development
of safe metabolic modulators for AD treatment represents a consider-
able challenge.
Previously, we have synthesized several tricyclic pyrone compounds
based on the structures of pyripyropene A, a potent acyl-
CoA:cholesterol O-acyltransferase inhibitor (Omura et al., 1993), and
arisugacin, a potent acetylcholinesterase inhibitor (Hua et al., 1997;
Omura et al., 1995). One of the compounds, CP2, was found to attenuate
Aβ-induced toxicity in primary cortical neurons (Maezawa et al., 2006)
and reduceAβ aggregation in 5× transgenic animalmodel of familial AD
(Hong et al., 2009). Here, we report thatmild inhibition ofmitochondri-
al complex I with tricyclic pyrone compound CP2 reduces levels of both
Aβ andpTau and averts the development of cognitive and behavior phe-
notype in threemousemodels of FAD.We identiﬁed CP2 binding site in
the redox center of complex I, and deﬁned the molecular mechanism
that involves activation of AMPK and restoration of axonal trafﬁcking.
Our results provide compelling evidence that modulation of complex I
activity represent promising and alternative therapeutic strategy for AD.
2. Material and Methods
2.1. Chemicals
CP2 was synthesized as described by Hua et al. (2003) and puriﬁed
using HPLC.
2.2. Animals
Animal care and handling procedures were approved by the Mayo
Clinical Institutional Animal Care and Use Committee in accordance
with the National Institutes of Health's Guide for the Care and Use of Lab-
oratory Animals. Details utilized animalmodels, treatment regimens and
behavior and memory tests are presented in Supplemental Experimen-
tal Procedures.
2.3. Gene Expression
Hippocampal tissue from untreated and CP2-treated (4 months)
APP/PS1 (n= 5) and NTG (n= 5) mice was examined for the markersof inﬂammation (iNOS, RANTES and interferon-gamma), cholesterol ef-
ﬂux (ABCA1 and ABCG1) and housekeeping gene (β-actin). Total RNA
was extracted with RNeasy kit (Qiagen). Gene expression assay (real
time qPCR) was performed with the primers/probe kit (Applied
Biosystem Inc.) according to the manufacturer's protocol. The expres-
sion levels of each gene from each group of animals were calculated as
per cent of the expression relative to the control NTG animals after nor-
malization for β-actin. Experiments were repeated twice in two inde-
pendent cohorts.
2.4. Neuronal Cultures
Primary hippocampal and cortical neurons were cultured as de-
scribed by Trushina et al. (2012). Neurons from neonatal animals (P1)
were isolated and plated from individual pups; genotyping was done
prior to the day of experiment. All experiments were performed in neu-
rons 7 days in culture unless speciﬁcally stated. Details are described in
Supplemental Experimental Procedures.
2.5. CP2 Quantiﬁcation
Animals were euthanized via cervical dislocation. Organs were har-
vested on ice and immediately ﬂash frozen in liquid nitrogen. On the
day of analysis, tissue was homogenized, and CP2 was extracted with
a mixture of ethyl acetate and 1-propanol (9:1), and analyzed using
LC/MS/MS mass spectrometer. Benzenetetracarboxylic acid (BTA) was
used as an internal standard (see Supplemental Experimental Proce-
dures for details).
2.6. Brain Amyloid
Amyloid plaques were visualized using immunoﬂuorescence label-
ing and confocal microscopy as previously described (Maezawa et al.,
2004). Three brain sliceswere examined fromeachmouse. Average par-
ticle size of the plaques was quantiﬁed using Image J 1.45
(rsbweb.nih.gov/ij/) (see Supplemental Experimental Procedures for
details).
2.7. Aβ ELISA
Soluble Aβ levels were determined in brain tissue isolated fromCP2-
treated APP/PS1 mice 7 months old (Kanekiyo et al., 2013). Details are
presented in Supplemental Experimental Procedures.
2.8. Axonal Trafﬁcking
Imaging ofmitochondrial trafﬁcking in live cortical neurons and data
analysis was done as described by Trushina et al. (2004, 2012). Details
are described in Supplemental Experimental Procedures.
2.9. Subcellular Fractionation and CP2 Localization
Cortical neurons and brain tissue from animals treated with CP2 for
4 months were homogenized, and subcellular fractionation was done
using differential centrifugation as described by Okado-Matsumoto
and Fridovich (2001). Concentration of CP2 in cellular fractions was de-
termined using LC/MS/MS as described above.
2.10. Mitochondrial Respiration
Mitochondrial respiration and rate of glycolysis was determined in
cortical neurons (E17) isolated fromWTmice using an XF24 Extracellu-
lar Flux Analyzer (Seahorse Biosciences, North Billerica,MA, USA) as de-
scribed by Wu et al. (2007). Details of experiment are described in
Supplemental Experimental Procedures.
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ATP, ADP andAMP levels in neurons and brain tissuewere estimated
usingHPLC. Details of experiment are described in Supplemental Exper-
imental Procedures.
2.12. Citrate Synthase Assay
The citrate synthase activity was determined in brain tissue of CP2-
treated and untreatedWT and APP/PS1mice (n=5per each group) ac-
cording to the manufacturer's instructions (Sigma-Aldrich, Co.).
2.13. Activity of Complexes I–V
Complex I–V enzymatic activity was measured photometrically
(Spinazzi et al., 2012). Details of experiment are described in Supple-
mental Experimental Procedures.
2.14. NAD+/NADH Levels
WT cortical neurons were treated with vehicle (0.001% DMSO) or
different concentrations of CP2 for 24 h before NAD+/NADH levels
were determined using Luminescence assay (Promega) according to
the manufacturer's instructions.
2.15. H2O2 Treatment
WT cortical neurons were pre-treated with different concentrations
of CP2 for 24 h, after that 1 mM H2O2 was added for 2 h. Cell viability
was determined using CellTiter-Glo® Luminescent Cell Viability Assay
(Promega) according to the manufacturer's instructions.
2.16. Transmission Electron Microscopy
EM images of hippocampal brain tissue from FADmicewere obtain-
ed as described by Trushina et al. (2012).
2.17. Western Blotting
Western blottingwas conducted as described (Trushina et al., 2012);
see Supplemental Experimental Procedures for details.
2.18. Theoretical Model of the CP2-Bound FMN Subunit of Human Mito-
chondrial Complex I
For details on low-mass molecular dynamics simulations see Sup-
plemental Experimental Procedures.
2.19. Data Analysis
Statistical analyses of means for more than two groups were per-
formed using one-way analysis of variance (ANOVA) with the catego-
ries of genotype and age as independent factors followed by the
Newman–Keuls post-hoc test for multiple comparisons. For analyses
of means involving only two groups with a sample size n b 30, the F-
test was used to determine if the variances between the two groups
were signiﬁcantly different. For samples with a signiﬁcant difference
in variance, theWelch's t test was applied. Two-tailed t-test was applied
for the samples with an insigniﬁcant difference in variance or where
n ≥ 30. The null hypothesis was rejected at the 0.05 level. All statistical
computations were carried out using Prism (Graphpad Software). Axo-
nal trafﬁcking videos were manually analyzed using LSM Image Brows-
er (version 4.2, Zeiss Microimaging, Thornwood, New York, USA)
(Trushina et al., 2012). Unpaired t-test with Welch's correction was
used for analyzing axonal trafﬁcking data. In all cases, α= 0.05 wasconsidered signiﬁcant. All values are presented as mean ± standard
error.
3. Results
3.1. CP2 Averts Cognitive and Behavior Phenotype in FAD Mice
We have previously identiﬁed small molecule tricyclic pyrone CP2
(Fig. 1A) that protects cells against Aβ toxicity, and reduces brain Aβ
in 5× FAD mice (Hong et al., 2009; Maezawa et al., 2006). To examine
the molecular mechanism, we ﬁrst tested whether CP2 penetrates the
blood–brain barrier (BBB). C14-Labeled CP2 was injected intraperitone-
ally to wild type (WT) mice, and levels were measured in the brain tis-
sue 30 min post-injection (Fig. S1A, B). Results suggest that CP2 rapidly
accumulates in the brain. Additional pharmacokinetics studies conduct-
ed in plasma of WT mice after intravenous or oral administration dem-
onstrated that CP2 bioavailability is 43% (Fig. S1C, D).
To examine the effect of CP2 administration on the development of
behavior and memory phenotype in vivo, breeding heterozygous APP
and PS1 mice were treated with 25 mg/kg/day CP2 in drinking water
and progeny with all four genotypes were produced with the expected
ratio (Fig. 1B). F1 animals continued to receive CP2 through life till
14 months of age. F1 APP and PS1 heterozygous mice also produced
multiple litters (Fig. 1B, F2). CP2-treated P and F1 mice were well
groomed, displayed no physical differences compared to non-
transgenic (NTG) littermates, with fecundity prolonged up to
14 months of age, while untreated counterparts were heavier and
stopped producingprogeny earlier in life (Figs. 1C, D and S2). Histopath-
ological examination of newborn F2 mice treated in utero and F1 mice
treated through life (Fig. 1B) demonstrated lack of developmental or
other abnormalities. Average concentration of CP2 in the brain of new-
bornmicewas ~90 μM, and in adult mice ~130 μM, regardless of the du-
ration of treatment (Table S1). Highest concentrations were found in
brain, heart, and reproductive organs, while levels in the liver were
the lowest (Table S2).
The effect of chronic CP2 treatment starting in utero on the develop-
ment of memory and behavior phenotype was determined with a bat-
tery of techniques. CP2-treated 56-weeks old APP and PS1 mice
performed signiﬁcantly better on hanging bar and on the rotating rod
(Fig. 1E, F) compared to NTG mice and untreated counterparts. Results
of novel object recognition (NOR) test conﬁrmed the development of
progressive memory deﬁcit in untreated PS1 and APP mice starting at
30 weeks of age (Fig. 1G, H). In contrast, CP2-treated FAD mice did not
demonstrate cognitive impairment at any age tested (Fig. 1G, H).
We next investigated whether CP2 administered to adult pre-
symptomatic mice delayed the onset of the disease. Double transgenic
APP/PS1 mice have accelerated AD phenotype with amyloid deposition
and altered behavior in Y-maze present at 3 months of age (Holcomb
et al., 1998). APP/PS1 mice treated with CP2 starting at 2.5 months of
age (Fig. 2A) outperformed their untreated counterparts in the hanging
bar test and maneuvering on accelerating rod evident after 4 months of
treatment (Fig. 2B, C), and did not develop anxiety in the open ﬁeld test
(Fig. 2D). Similar to APP and PS1mice, CP2 treatment averted the devel-
opment of cognitive decline in APP/PS1 animals preserving the ability to
discriminate between novel and familiar objects (Fig. 2E). Memory pro-
tection was detected after 2 months of treatment. In the T-maze, CP2-
treated APP/PS1 mice displayed higher percentage of spontaneous al-
ternations compared to NTG or untreated APP/PS1 animals, indicating
a superior working memory and intact exploratory behavior (Fig. 2F).
3.2. CP2 Treatment Reduces Soluble and Insoluble Aβ
Levels of amyloid beta in the brain tissue of CP2-treated and untreat-
ed FAD mice were established using confocal microscopy (Maezawa
et al., 2004).We found that treatment for 4months starting at presymp-
tomatic age of 2.5 months (Fig. 2A) resulted in a 50% reduction in
Fig. 1. Chronic CP2 treatment averts thedevelopment of behavior andmemory phenotype in FADmice. (A) CP2 structure. (B) P and F1 animals treatedwith 25mg/kg/day CP2 produced F1
progeny thatwere treatedwith CP2 till 14months of age. F2 pupswere used for axonal trafﬁcking experiments. (C, D) CP2-treated PS1 (C, light gray; n= 5) and APP (D, light gray, n= 5)
micemaintained bodyweight similar to NTGuntreatedmice (black, n=10),while untreated PS1 (C, dark gray, n=10) andAPP (D, dark gray, n=10)mice accumulatedweightwith age.
*P b 0.05. (E) CP2-treated APP mice (red, n = 5) did not display muscle weakness or altered prehensile reﬂex in hanging bar test compared to untreated APP animals (gray, n = 10).
Black — untreated NTG, n = 10. *P b 0.05. (F) Time on a rod rotating at 20 rpm. CP2-treated PS1 (orange, n = 5) and APP (dark blue, n = 5); untreated APP (light blue, n = 10), PS1
(gray, n = 10), and NTG mice (black, n = 10). Mice were 56 weeks old. *P b 0.05. (G, H) NOR test demonstrates that CP2-treated APP (G, light orange bars: training session; red bars:
NOR, n = 5) and PS1 (H, light blue bars: training session; dark blue bars: NOR, n = 5) mice maintained the ability to recognize a familiar object similar to NTG animals (n = 10)
while their untreated counterparts (n = 10 for APP and n = 10 for PS1) lost that ability with age. *P b 0.05. See also Figs. S1 and S2.
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similar to our previous results in 5× FAD mice (Hong et al., 2009)
(Figs. 3A and S3). CP2-treated APP/PS1 mice also had a signiﬁcant de-
crease in the levels of soluble Aβ42 detected using ELISA (Fig. 3B, C).
These data suggest that cognitive protection induced by CP2 is accom-
panied with signiﬁcant decrease in brain Aβ.
3.3. Modulation of Complex I Activity Augments Mitochondrial
Bioenergetics
We next assessed CP2 localization in cortical neurons and brain tis-
sue of WT and APP/PS1 mice. Subcellular fractionation and HPLC analy-
sis revealed that CP2 accumulated in enriched mitochondrial fractions
isolated from CP2-treated neurons in vitro (Fig. 3D, E). Similar, CP2 pre-
dominantly was detected in enriched mitochondrial fractions isolated
from different brain regions of CP2-treated WT and APP/PS1 mice
(Fig. S4). Notably, CP2 levelswere highest in themitochondrial fractions
from thehippocampus of bothWT andAPP/PS1mice compared to other
brain regions or nuclear or cytoplasmic fractions. Overall CP2 levelswere higher in all fractions in APP/PS1 mice compared to WT animals
consistent with its reported ability to bind Aβ (Hong et al., 2009).
To evaluate whether CP2 affects mitochondrial bioenergetics, we si-
multaneouslymeasured oxygen consumption rate (OCR) and glycolysis
(ECAR, extracellular acidiﬁcation rate) in intact WT cortical neurons
using a Seahorse XF24 extracellular ﬂux analyzer (Figs. 4 and S5A, B).
We found that CP2-treated neurons exhibited signiﬁcantly lower basal
OCR relative to the vehicle-treated cells (Fig. 4A, B). We next investigat-
ed whether CP2 affected individual components of electron transport
chain (ETC) by adding speciﬁc pharmacological inhibitors to CP2-
treated and untreated cells and measuring OCR (Fig. 4A, B). A decrease
in OCR after the addition of the Complex V inhibitor oligomycin was
compatible in treated and untreated neurons indicating that CP2 did
not affect ATP synthase (Fig. S5B). However, we found that CP2 signiﬁ-
cantly augmented spare respiratory capacity (SRC) evident as an in-
crease in OCR in response to the addition of mitochondria uncoupler
FCCP (Figs. 4A, B and S5B). SRC is an indicator of themitochondrial abil-
ity to produce additional energy under conditions of increased work-
load or stress, which is essential for long-term cellular survival and
Fig. 2. CP2 treatment of pre-symptomatic APP/PS1mice prevents the development of AD. (A) Treatment regimen in pre-symptomatic APP/PS1 (A/P) mice. (B, C) CP2 protects against the
development of motor phenotype evident by the unaltered performance on a hanging bar (B) and accelerating rod (C) after 4months of treatment. Squares—WT; triangles—WT+CP2;
diamonds— A/P; circles — A/P + CP2. *P b 0.05; **P b 0.01; ***P b 0.001; n = 8–9 mice per group. (D) A/P mice (circles) treated for 4 months demonstrated normal activity in the cage
similar to untreated (squares) and CP2-treated (triangles) WTmice compared to the untreated A/P animals (diamonds). *P b 0.05; **P b 0.01 A/P compared to WT; ##P b 0.01 A/P + CP2
compared to A/P; n= 8–9mice per group. (E) NOR test. *P b 0.05; **P b 0.01; n= 5–10mice per group. (F) After 4months of treatment, A/Pmice performed similar toWT animals during
spontaneous T-maze exploration while untreated A/P mice displayed prominent memory deﬁcit. *P b 0.05. Data are presented as mean ± SEM.
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apparent (Fig. 4D) and respiratory control ratio (Fig. 4E), and reduced
proton leak (Fig. 4B), which together suggest that ETC in neurons was
tightly coupled (Fig. 4C) providing mitochondria with a considerable
bioenergetics reserve and enhanced ability to sustain stress. Indeed,
CP2-treated neurons exhibited signiﬁcantly greater resistance to
H2O2-induced oxidative damage compared to untreated neurons
(Fig. 4F). Reduced respiration could lead to the upregulation of glycolyt-
ic pathway. However, the decrease in OCR in response to oligomycin in
CP2-treated neurons did not increase ECAR (Fig. 4G) indicating lack of
shift to glycolysis. Thus, CP2 reducesmitochondrial respiration and aug-
ments bioenergetics without activating glycolytic pathway.
To further investigate the mechanism of CP2-induced reduction in
basal OCR, we substituted speciﬁc inhibitors of ETC and FCCP with
CP2, one at a time, and evaluated whether CP2 prompts changes in
OCR similar to any of the mitochondrial toxicants (Fig. 4H). Addition
of CP2 to intact WT neurons induced changes similar to rotenone/
antimycin A but not oligomycin or FCCP suggesting that CP2 inhibitscomplexes I and/or III (Fig. 4H). To conﬁrm theseﬁndings, we examined
the effect of CP2 on the activity of each of the respiratory complexes
using enzymatic assays and mitochondria isolated from the brain of
WTmice (Fig. 5A). The addition of CP2 did not alter the activity of com-
plexes II, III, IV and V, while complex I activity was inhibited in a dose-
dependent manner. However, the effect was mild compared to 80% of
inhibition induced under the same experimental conditions by 10 μM
of rotenone (data not shown). It is well known that inhibition of com-
plex I could increase production of reactive oxygen species (ROS) con-
tributing to neurodegenerative processes (Dumont and Beal, 2011).
Nevertheless, the expression of oxidant-inducible gene, heme
oxygenase-1 (HO-1) (Nath et al., 2001), or genes related to inﬂamma-
tion (iNOS, RANTES and interferon-gamma, IFNγ) was not affected in
the brain tissue of FAD mice after 4 or 14 months of CP2 treatment
(Figs. 5B, C and S6).Moreover, there appears a trend toward a reduction
in expression of HO-I, iNOS, IFNγ in hippocampus of CP2-treated FAD
animals. We previously reported that CP2 modestly inhibited the activ-
ity of Acyl-CoA:cholesterol acyltransferase, which could increase the
Fig. 3. CP2 reduces amyloid levels and accumulates inmitochondria. (A) Amyloid plaques
in the brain of APP/PS1 mice (blue, n = 5) treated for 4 months are signiﬁcantly reduced
compared to untreated animals (red, n = 5). *P b 0.05. (B, C) Soluble Aβ42 (C) but not
Aβ40 (B) is reduced in APP/PS1 mice treated for 6 months (blue, n = 9) compared to un-
treated animals (red, n = 9). *P b 0.05. (D) CP2 accumulates in mitochondria (HM) frac-
tions isolated from WT neurons treated with 2 μM CP2 for 24 h. CN — crude nuclear;
CYTO — cytoplasmic fractions. (E) Purity of HM fractions conﬁrmed using EM (scale bar,
1 μm) and Western blotting. Tom 20 — mitochondrial marker; NP — nucleoporin. See
also Figs. S3 and S4.
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ever, gene expression analysis failed to detect activation of cholesterol
transporter genes ABCA1 or ABCG1 suggesting that therapeutic effect
of CP2 was not related to enhanced cholesterol efﬂux (Fig. S6). We
next assayed the activity of citrate synthase, an enzyme of the mito-
chondrialmatrix that is amarker of organelle integrity and oxidative ca-
pacity. Citrate synthase activity in mitochondria isolated from brain
tissue of CP2-treated APP/PS1 mice was similar to the observed in WT
animals (Fig. S5C) suggesting that CP2 does not damage inner mito-
chondrial membrane causing leakage of the matrix and does not affect
oxidative capacity or TCA cycle. These results are also supported by elec-
tron microscopy examination demonstrating robust mitochondrial
morphology and cristae organization in the hippocampus of APP, PS1
and APP/PS1 mice treated with CP2 through life (Fig. 5D).
Furthermore, low-mass molecular dynamics simulations (Pang,
2014) suggest that the cationic CP2 molecule competes with ﬂavin
mononucleotide (FMN) for binding to the redox subunit of human mi-
tochondrial complex I (Fig. 5E, F). FMN is involved in the oxidation of
nicotinamide adenine dinucleotide NADH to NAD+ (Hirst et al., 2003).
Indeed, treatment of WT neurons with CP2 increased levels of NADH
in a dose-dependentmanner compared to vehicle or an inactive CP2 an-
alog, a neutral tricyclic pyrone compound TP17 (Hong et al., 2009)
(Fig. 5G). However, inhibition of complex I by CP2 did not lead to a sig-
niﬁcant drop in the cellular NAD+ concentration (Fig. 5G). These com-
putational and biochemistry studies indicate that competition forbinding at the FMN subunit partially reduces complex I activity without
inducing oxidative damage or inﬂammation in vivo.
3.4. Modulation of Complex I Activates AMPK In Vitro and In Vivo
We next measured ATP, AMP and ADP in vitro in primary neurons
and in brain tissue of CP2-treated animals (Fig. 6A–G). Modulation of
complex I activity resulted in reduced ATP levels in neurons and dose-
and time-dependent increase in AMP/ATP and a decrease in ATP/ADP
ratio (Fig. 6A–D) consistent with previously shown decrease in mito-
chondrial respiration (Fig. 4A, B). Similarly, reduced ATP, increased
AMP levels and AMP/ATP ratio was detected in the brain tissue of
CP2-treated WT and APP/PS1 mice (Fig. 6E–G). Increase in AMP/ATP is
a known activator of AMPK, a major energy sensor in the cell
(Shirwany and Zou, 2014). Indeed, CP2 treatment increased levels of
pAMPK (Thr172), an activated form of the kinase, in neurons from
APP/PS1 mice in time-dependent manner (Figs. 6H and S7A), and in
the brain tissue of WT and APP/PS1 animals in vivo (Figs. 6I and S7B).
AMPK negatively regulates the activity of glycogen synthase kinase 3
beta (GSK3β), which in turn could affect tau phosphorylation (Horike
et al., 2008; Park et al., 2012). Indeed, CP2-dependent activation of
AMPK resulted in concomitant increase in the inhibitory phosphoryla-
tion of GSK3β at Ser9 and marked reduction of tau phosphorylation at
Ser396/404 in neurons in vitro and in APP/PS1 mice in vivo (Fig. 6H, I).
3.5. CP2 Restores Axonal Trafﬁcking
We previously reported that inhibition of axonal trafﬁcking was de-
tected early in embryonic neurons from PS1 and APP/PS1 mice
(Trushina et al., 2012). Increased levels of Aβ, pTau and activated
GSK3β are implicated in the development of axonal trafﬁcking dysfunc-
tion in AD (Vicario-Orri et al., 2015).Wenext exploredwhether changes
induced by modulation of complex I activity positively affected axonal
transport. Using established methodology (Trushina et al., 2004, 2012)
(Fig. 7A–C), we evaluated mitochondrial motility in neurons from F2
pups treated with CP2 in utero (Fig. 1B). Visualization of mitochondrial
dynamics in live neurons revealed lack of trafﬁcking inhibition in APP/
PS1 and PS1 mice in both anterograde and retrograde directions
(Fig. 7B–D) and signiﬁcant increase in motile organelles (Fig. 7E).
Since CP2 levels were similar in the brain tissue of neonatal F2 and
adult FAD animals (Table S1, P1), we examinedwhether axonal trafﬁck-
ing was also improved in adult mice in vivo by measuring levels of
brain-derived neurotrophic factor (BDNF) in APP/PS1 mice treated
with CP2 for 2 months (Fig. 7F). BDNF provides an essential support
for synaptic function, plasticity and neuronal survival. It is delivered to
the cell body via retrograde trafﬁcking, and its reduced availability is
among the most devastating consequences of axonal trafﬁcking inhibi-
tion (Poon et al., 2011). Restoration of axonal transport and improved
BDNF support could positively affect levels of synaptic proteins. Indeed,
we found signiﬁcant increase in synaptophysin and BDNF in brain tissue
of CP2-treated APP/PS1 mice (Fig. 7F–I) consistent with preserved cog-
nitive function.
4. Discussion
We present evidence that modulation of cellular energetics via mild
inhibition of mitochondrial complex I reduces levels of both Aβ and
pTau and averts the development of cognitive phenotype in multiple
FAD mice. Using low-mass molecular dynamics simulations and multi-
ple biochemical approaches, we identiﬁed that CP2 competes with
FMN for binding to the redox center of human mitochondrial complex
I. We conducted comprehensive animal studies utilizing three distinct,
transgenic mouse models of FAD with early and late disease onset and
two treatment regimens that demonstrate unequivocal protection of
mice against cognitive decline as well as enhanced vigor and fecundity
relative to untreated groups. We also performed in-depth evaluation
Fig. 4. CP2 augments mitochondrial bioenergetics in neurons. (A–E) Bioenergetics parameters estimated inWT cortical neurons treated with 2 μM CP2 (24 h, gray) compared to vehicle-
treated neurons (black). Data are mean± SEM; n= 12–14 replicates per data point, three independent experiments. OCR— oxygen consumption rate; SRC— spare respiratory capacity;
non-mito — non-mitochondrial respiration; AA — antimycin A. Coupling efﬁciency is presented in (C). *P b 0.05; **P b 0.01; ***P b 0.001 (Student's t-test). (F) CP2 protects WT neurons
against H2O2 toxicity. **P b 0.01; ***P b 0.001 (Student's t test). (G) CP2 treatment does not induce glycolysis. Temporal bioenergetic proﬁling in neurons generated as in (A) after addition
of: A— oligomycin, B— FCCP, and C— rotenone (n= 12–14 replicates per data point, three independent experiments). (H) CP2 mimics the effect of rotenone/AA; n = 7. See also Fig. S5.
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in cellular energetics led to an increase in AMP/ATP ratio and activation
of AMPK,with subsequent reduction in GSK3β and restoration of axonal
trafﬁcking (Fig. 7J). Our ﬁndings demonstrate that modulation of mito-
chondrial function by small-molecule therapeutics could effectively and
safely modify or prevent the development of disease validating promis-
ing and alternative therapeutic strategy for AD thatmay offer a practical
treatment to patients.
Complex I is the largest and most complicated enzyme of the mam-
malian OXPHOS systemwhere function of its 45 subunits is not entirely
understood. Deﬁciencies in complex I are associated with various dis-
eases including Parkinson's disease, Huntington's disease (HD) and AD
(Orth and Schapira, 2001). Complex I is also one of the main contribu-
tors to ROS production (Hirst et al., 2008). However, CP2-dependent in-
hibition of complex I did not induce oxidative damage, inﬂammation or
changes in mitochondrial morphology. Contrary, CP2 augmented mito-
chondrial bioenergetics increasing SRC and ETC coupling efﬁciency, con-
ferring neurons with greater ability to resist stress. Chronic treatment
for 14 months provided robust preservation of cognitive and motorfunctions in FAD animals compared not only to untreated counterparts
but also to WT mice. The beneﬁcial metabolic adaptation observed in
our study may be related to the speciﬁc site of CP2 binding to complex
I that is encoded by the NADH-ubiquinone oxidoreductase 1 alpha
subcomplex subunit 1 (NDUFA1). It is interesting to note that partial de-
ﬁciency induced by neuron-speciﬁc conditional ablation of another sub-
unit of complex I, NDUFA5, also did not increase oxidative damage or
inﬂammation, but contrary to our data, caused mild chronic encepha-
lopathy inmice (Peralta et al., 2014).Moreover, different from rotenone
that binds at or close to the ubiquinone binding site(s) of complex I
leading to substantial ROS generation (Darrouzet et al., 1998), binding
at the FMN subunit can actually reduce levels of ROS by inhibiting the
reaction of semiquinone species with O2 that occurs at the ﬂavin center
(King et al., 2009). It is also important to note that the extent of complex
I inhibition by CP2 wasmild. Thus, it did not signiﬁcantly affect the pool
of NAD+. At the same time, it is feasible that moderate shift of the equi-
librium toward NADH detected in our studies could have an additional
beneﬁt compensating for a decline in its neuronal levels associated
with age and AD (Parihar and Brewer, 2007). Moreover, since inhibition
Fig. 5. CP2 binds to the ﬂavin mononucleotide subunit of complex I and inhibits its activity without inducing oxidative stress. (A) Activity of respiratory complexes I–V in isolated mito-
chondria treated with different concentrations of CP2. *P b 0.001, two-tailed t-test; n = 3–5 replicates per data point. (B, C) CP2 treatment in APP (25 mg/kg/day, 14 months, n = 4) and
APP/PS1 (25 mg/kg/day, 4 months, n = 5) mice did not change the expression of HO-1 (B) and iNOS (C) genes compared to untreated NTG (n = 4) or WT mice (n = 5). (D) Electron
micrographs of mitochondria in the hippocampus of APP mouse treated with CP2 for 14 months (bottom) compared to untreated APP mouse (top) of the same age. Scale bar, 500 nm
(top) and 200 nm (bottom). (E) Overview of the CP2-bound ﬂavinmononucleotide subunit of human complex I. (F) Residues of the complex I subunit that interact with CP2 (the subunit
is in stickmodel; CP2 is in ball-and-stickmodel; dashed lines denote hydrogen bonds). (G) Levels of NADHandNAD+ inWTneurons treatedwith different concentration of CP2, vehicle or
inactive CP2 analog, TP17; n = 8–11 replicates per data point. ***P b 0.00001. See also Fig. S6.
301L. Zhang et al. / EBioMedicine 2 (2015) 294–305of complex IV is predominantly linked to Aβ pathology (Chaturvedi and
Flint Beal, 2013), reducing workload through ETC by mild inhibition of
complex I could also provide some relief for complex IV. While the de-
tailed correlation between the extent of deﬁciencies in various ETC
complexes and efﬁcacy of CP2 treatment remains to be determined,
our pilot data demonstrate that CP2 treatment is efﬁcient in slowing
down the development of AD when administered for 6 months to
symptomatic APP/PS1 mice starting at 9 months of age (data not
shown).
Another important ﬁnding of our study is that mild inhibition of
complex I resulted in restoration of axonal trafﬁcking. Remarkably,
reduction in GSK3β activity, Aβ and pTau was sufﬁcient to restore
mitochondrial motility even under conditions where ATP production
was slightly reduced. Increased levels of BDNF and synaptic proteinssupport the notion that trafﬁcking restoration contributes to cogni-
tive protection observed in APP/PS1 mice. These data demonstrates
therapeutic value of trafﬁcking restoration in respect to cognitive
protection. We previously demonstrated that CP2 binds Aβ
preventing its aggregation (Maezawa et al., 2006; Rana et al.,
2009). However, it remains to be determined to what extent that
contributes to therapeutic efﬁcacy observed in the study. While we
detected a reduction in Aβ levels, future investigations are needed
to establish whether CP2 affects APP processing, Aβ production
and/or enhances autophagic clearance via AMPK-dependent inhibi-
tion of the mammalian target of rapamycin.
Our data support a counterintuitive therapeutic approach that is
based on the inhibition of OXPHOS. However, emerging data demon-
strate that the presence of mtDNA mutations encoding subunits of
Fig. 6. CP2 treatment increases AMP/ATP ratio and activates AMPK in vitro and in vivo. (A, B) Dose-dependent increase in AMP/ATP (A) and a decrease in ATP/ADP (B) inWT neurons 24 h
after CP2 treatment. *P b 0.05; ***P b 0.001; n = 6. (C, D) Time-dependent AMP/ATP increase (C) and ATP/ADP decrease (D) in WT cortical neurons after CP2 treatment. *P b 0.05;
***P b 0.001; n = 6; VEH — vehicle-treated neurons. Data represent mean ± SEM. (E–G) CP2 (25 mg/kg/day, 2 months) reduces ATP levels in the brain of WT (n = 16) and APP/PS1
(A/P, n = 11) mice (E), and increases levels of AMP (F) and AMP/ATP ratio (G). *P b 0.05; **P b 0.01; ***P b 0.001. (H) CP2 affects levels of pAMPK, pGSK3β (S9), and pTau (S396) in a
time-dependent manner in cortical neurons (P1) from APP/PS1 mice. Each lane represents neurons from individual APP/PS1 animal. (I) CP2 (25 mg/kg/day, 2 months) activates AMPK,
reduces activity of GSK3β, and decreases levels of pTau (S396) in the brain of APP/PS1 mice. See also Fig. S7.
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beneﬁcial in preventing obesity and type II diabetes (Pospisilik et al.,
2007; Quintens et al., 2013; Vernochet et al., 2012; Wredenberg et al.,
2006), and promoting longevity in model organisms and in humans
(Copeland et al., 2009; Lee et al., 2003; Liu et al., 2005; Raule et al.,
2014). Activation of AMPK also underlies molecular mechanisms of
metabolic reprogramming induced by calorie restriction (Martin-
Montalvo and de Cabo, 2013). While we did not detect signiﬁcant
changes in levels of Sirtuin 1 or peroxisome proliferator-activated re-
ceptor gamma coactivator 1 alpha after prolonged treatment with CP2
(data not shown), animals maintained healthy body weight, displayed
robust performance in motor tests, and were conceiving longer com-
pared to untreated mice. It will be important to further investigate the
molecular mechanisms associated with cognitive protection observed
in our study and to determine whether metabolic reprogramminginduced by this complex I inhibitor could promote an increase in health
and life span.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.03.009.Author Contributions
E.T. conceptualized and supervised the study, and wrote the manu-
script; P.D., S.Z., and E.N. measured AMP–ADP; E.T., P.M., and B.G. exam-
ined axonal transport; I.M., L.-W.J., Y.Y., T.K., and G.B. quantiﬁed Aβ;
KO.C. and K.N. performed gene expression; K.P. and T.D.T.N. synthe-
sized/quantiﬁed CP2 and amyloid plaques; D.H.H. designed and provid-
ed CP2 and analyzed data; Y.-P.P. designed and conducted the
computational study. All authors participated in manuscript revisions.
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